The drugs' long-term safety and the incidence of ovarian hyperstimulation syndrome, the most immediate and potentially fatal complication, remain open to debate, even as the clinics offering them have become a multibillion-dollar industry serving hundreds of thousands of women a year.
Source
No comments:
Post a Comment